Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the body’s natural immune system as well as some therapies. A new study uses novel ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A Phase 2, Multicenter, ...
Scientists are nearing a breakthrough in using CRISPR gene-editing to eliminate HIV from human DNA. Early trials of EBT-101 ...
HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.
UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
In July 2024, we published a story with the headline: "One of the 7 people cured of HIV tells his story. Can his cure work for others." This summer, at the International AIDS Society conference, came ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback